News
Top 3 Health Care Stocks That May Collapse In Q2
12 Apr 24
News, Penny Stocks, Short Ideas, Pre-Market Outlook, Markets, Trading Ideas
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $45
12 Apr 24
News, Price Target, Analyst Ratings
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $46
12 Apr 24
News, Price Target, Analyst Ratings
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
10 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Raymond James Upgrades Revolution Medicines to Strong Buy, Raises Price Target to $48
10 Apr 24
News, Upgrades, Price Target, Analyst Ratings
What's Going On With Revolution Medicines Stock?
10 Apr 24
News, Movers
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
10 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Revolution Medicines Announces Publications On The Discovery And Preclinical Profile Of Representative Of A New Class Of RAS(ON) Multi-Selective Inhibitors Designed To Block Full Spectrum Of Oncogenic RAS(ON) Proteins
8 Apr 24
Biotech, News, General
Needham Maintains Buy on Revolution Medicines, Maintains $36 Price Target
8 Apr 24
News, Price Target, Analyst Ratings
Piper Sandler Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $43
11 Mar 24
News, Price Target, Initiation, Analyst Ratings
Morgan Stanley Maintains Equal-Weight Rating for Revolution Medicines: Here's What You Need To Know
8 Mar 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $44
8 Mar 24
News, Price Target, Analyst Ratings
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $42
27 Feb 24
News, Price Target, Analyst Ratings
Earnings Scheduled For February 26, 2024
26 Feb 24
Earnings
Revolution Medicines's Earnings: A Preview
23 Feb 24
Earnings
Press releases
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
9 Apr 24
Health Care, Press Releases
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
8 Apr 24
Health Care, Press Releases, General
Revolution Medicines to Participate in Upcoming Investor Conferences
4 Apr 24
News, Press Releases